Evidence map›Paper›PMID 26799422›Full record

ArticleOncotarget2016

Long intergenic non-coding RNA 00152 promotes tumor cell cycle progression by binding to EZH2 and repressing p15 and p21 in gastric cancer.

Wen-ming Chen, Ming-de Huang, Dao-ping Sun, Rong Kong, Tong-peng Xu, Rui Xia, Er-bao Zhang, Yong-qian Shu

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 3 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 130 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Cells · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. LINC00152 mediates CD8Journal of molecular histology · 2021
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Wen-ming ChenDepartment of Oncology, Jining NO.1 People's Hospital, Jining City, Shandong Province 272011, China.
Ming-de HuangDepartment of Medical Oncology, Huai'an First People's Hospital, Nanjing Medical University, Jiangsu Province 223300, China.
Dao-ping SunDepartment of Oncology, Jining NO.1 People's Hospital, Jining City, Shandong Province 272011, China.
Rong KongCentral Laboratory, Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu Province 225001, China.
Tong-peng XuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province 210029, China.
Rui XiaDepartment of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Er-bao ZhangDepartment of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Yong-qian ShuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province 210029, China.
Nanjing Medical University · CNHuaian First People’s Hospital · CNJiangsu Province Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) play important regulatory roles in several human cancers. Integrated analysis revealed that expression of long intergenic non-coding RNA 152 (LINC00152) was significantly upregulated in gastric cancer (GC). Further analysis in a cohort of 97 GC patients revealed that LINC00152 expression was positively correlated with tumor invasion depth, lymph node metastasis, higher TNM stage, and poor survival. Gene set enrichment analysis revealed that cell proliferation and cell cycle progression were increased in patients with high LINC00152 expression. In both GC cell lines and xenograft systems, LINC00152 overexpression facilitated GC cell proliferation by accelerating the cell cycle, whereas LINC00152 knockdown had the opposite effect. Moreover, by binding to enhancer of zeste homolog 2 (EZH2), LINC00152 promotes GC tumor cell cycle progression by silencing the expression of p15 and p21. These findings suggest that LINC00152 may play contribute to the progression of GC and may be an effective therapeutic target.

Indexed as

Cell CycleCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p21Enhancer of Zeste Homolog 2 ProteinFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingRNA-Binding ProteinsRNA, Long NoncodingStomach NeoplasmsCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p21Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanlong non-coding RNA Linc00152, humanRNA-Binding ProteinsRNA, Long Noncodingcell proliferationgastric cancerLINC00152long non-coding RNAp15/p21

Identifiers

PMID26799422
PMCPMC4891083
OpenAlexW2269340112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.